INOVIO Pharmaceuticals (INO) Stock Climbs On COVID-19 Vaccine Data

Inovio Pharmaceuticals INO Stock News

INOVIO Pharmaceuticals Inc (NASDAQ: INO) is running for the top in the market this morning, and for good reason. The company announced positive data from its COVID-19 vaccine candidate. Here’ what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

INO Stock Climbs On COVID-19 Vaccine Data

In the press release, INOVIO Pharmaceuticals announced the publication of preclinical data surrounding INO-4800, the company’s DNA-based COVID-19 vaccine candidate. According to the release, the data showed robust neutralizing antibody and T cell immune responses against SARS-CoV-2, the virus that causes COVID-19.

In the release, INO said that the data was published in the peer-reviewed journal known as Nature Communications.

The company explained that INO-4800 targets a surface antigen Spike protein of SARS-CoV-2. In guinea pigs and mice, the vaccine generated robust binding and neutralizing antibodies as well as a strong T cell response.

In the study, the authors demonstrated virus neutralizing activity in three separate testing assays. These include an assay using live SARS-CoV-2 viruses, an assay using a pseudo-virus assay, and another using a novel high-throughput surrogate neutralization assay.

Importantly, study authors also found neutralizing antibodies in the lungs of vaccinated animals.

In a statement, Dr. Kate Broderick, SVP of R&D at INO and Team Lead for COVID-19 vaccine development, had the following to offer:

These positive preclinical results from our COVID-19 DNA vaccine (INO-4800) not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700. The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials.

The above statement was followed up by Dr. J. Joseph Kim, President and CEO at INO. Here’s what he had to offer:

INOVIO and our collaborators are working diligently to advance INO-4800 to help fight the current pandemic. We are planning to utilize these positive preclinical results along with our upcoming animal challenge data and safety and immune responses data from our Phase 1 studies to support rapidly advancing this summer to a large, randomized Phase 2/3 clinical trial.

This News Is Huge

INO is making incredible progress in the development of a COVID-19 vaccine. In fact, this data shows that the company now has two viable vaccine candidates. Let’s not forget the INO-4700 vaccine the company is working on that led to a traunch of CEPI funding.

With two viable vaccine candidates, INOVIO Pharmaceuticals is well ahead of most in the race to develop a vaccine. Should it be successful in doing so, the sky is the limit with regard to revenue growth as demand is likely to be incredibly high around the world. As such INO stock is one that’s well worth watching.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alertts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.